Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Lumakras Nears Japan Market, Amgen Eyes Simultaneous Launch with US for Next 5 Oncology Drugs: EVP
April 14, 2022
-
REGULATORY Chuikyo OKs Listing of 8 Drugs on April 20; Vyvgart, Lumakras, and More
April 13, 2022
-
REGULATORY Vyvgart, Pivlaz to Be 1st to Face Zero Premium Rule for Low Cost Disclosures
April 12, 2022
-
REGULATORY Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
-
BUSINESS Astellas, GSK, 2 Other Firms Log 10%-Plus Drop in Workforce: Jiho Poll
April 11, 2022
-
REGULATORY MHLW Set to Boost Recognition of Reporting System for Improper Drug Promotions
April 8, 2022
-
BUSINESS New Grad Hiring Down 4.4% in Spring 2022, Downtrend for Sales Reps Continues: Poll
April 7, 2022
-
BUSINESS Jardiance Now Allowed for Use in HFpEF Patients: Label Update
April 7, 2022
-
BUSINESS Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
-
BUSINESS Pfizer Tops 2021 Global Pharma Ranking on Vaccine Boon: Jiho Tally
April 6, 2022
-
REGULATORY SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
-
ORGANIZATION JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
-
REGULATORY Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
April 5, 2022
-
ORGANIZATION Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
April 4, 2022
-
REGULATORY Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
April 4, 2022
-
BUSINESS COVID-19 as Catalyst for Introducing Decentralized Clinical Trials in Japan; Some Results Due Out by Year-End
April 1, 2022
-
REGULATORY Japan PM Touts Proposed Emergency Approval Scheme as Bill Enters Diet Deliberations
April 1, 2022
-
REGULATORY 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
March 31, 2022
-
BUSINESS Novartis Stepping Up Population Health Initiatives in CV, Oncology Arenas to Solve Regional Challenges
March 30, 2022
-
REGULATORY Japan Approves Kerendia, Vabysmo, Ondexxya, Takhzyro and More
March 29, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…